Structure Therapeutics Inc. (GPCR)
NASDAQ: GPCR · Real-Time Price · USD
50.75
-2.75 (-5.14%)
Apr 17, 2026, 4:00 PM EDT - Market closed
Structure Therapeutics Employees
Structure Therapeutics had 220 employees as of December 31, 2025. The number of employees increased by 57 or 34.97% compared to the previous year.
Employees
220
Change (1Y)
57
Growth (1Y)
34.97%
Revenue / Employee
n/a
Profits / Employee
-$641,827
Market Cap
3.60B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 220 | 57 | 34.97% |
| Dec 31, 2024 | 163 | 70 | 75.27% |
| Dec 31, 2023 | 93 | 25 | 36.76% |
| Dec 31, 2022 | 68 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Telix Pharmaceuticals | 1,184 |
| ACADIA Pharmaceuticals | 798 |
| Crinetics Pharmaceuticals | 594 |
| Denali Therapeutics | 503 |
| Travere Therapeutics | 497 |
| Dyne Therapeutics | 258 |
| Edgewise Therapeutics | 146 |
GPCR News
- 3 days ago - Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel - GlobeNewsWire
- 16 days ago - What's Going On With Structure Therapeutics Stock On Wednesday? - Benzinga
- 4 weeks ago - Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate? - Barrons
- 4 weeks ago - Structure Therapeutics Stock Explodes As Much-Awaited Experimental Oral Drug Trial Shows Weight Loss Of 16% - Benzinga
- 4 weeks ago - Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron - GlobeNewsWire
- 7 weeks ago - Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights - GlobeNewsWire
- 2 months ago - Obesity stocks slump on Novo's underwhelming 2026 sales forecast - Reuters
- 3 months ago - Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s - CNBC